Oncology

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, discusses…

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, elected ASCO President for the 2015–2016 term, Julie M. Vose, MD, MBA, of the…

Jacqueline Barrientos, MD, of North Shore-LIJ Cancer Institute, Lake Success, NY, summarises recent progress in the treatment of chronic lymphocytic…

Axel Hauschild, MD, of University of Schleswig-Holstein, Kiel, Germany, reviews the clinical trial data for new treatments in melanoma presented at the…

University of Nebraska Medical Center, Omaha, NE, discusses the phase 3 CheckMate 067 trial of nivolumab alone or combined with ipilimumab versus…

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Georgina Long, BSc, PhD, MBBS, FRACP, of the University of Sydney, Sydney…

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Andrew B. Lassman, MD, of Columbia University Medical Center, New York, NY…

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, James Larkin, FRCP, PhD, of The Royal Marsden, London, UK, provides an overview…

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Patrick Schöffski, MD, of University Hospitals Leuven, Leuven, Belgium…

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, James Larkin, FRCP, PhD, of The Royal Marsden, London, UK, discusses the results…

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Geoffrey R. Oxnard, MD, of Dana-Farber Cancer Institute, Boston, MA, discusses…

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Université Paris…

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, María-Victoria Mateos, MD, PhD, of the University Hospital of Salamanca…

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sagar Lonial, MD, of the Winship Cancer Institute, Emory University, Atlanta, GA…

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Université Paris…

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ, discusses the results of…

Multivariate analysis of patients with acute myeloid leukaemia (AML) at day 28 in clinical or pathologic complete remission showed that DNMT3A R882…

The randomised, controlled phase 2 SORAML trial showed that the addition of the tyrosine kinase inhibitor, sorafenib, to chemotherapy improved event-free…

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, James Larkin, FRCP, PhD, Consultant Medical Oncologist at The Royal Marsden…

In the phase 3 NCCTG N0574 (Alliance) trial, patients with 1 to 3 small brain metastases were randomised to receive stereotactic radiosurgery (SRS) alone…

A phase 3, randomised controlled trial showed that elective neck dissection improved overall survival by 12.5% and reduced risk of death by 36% when…

Data from the Childhood Cancer Survivor Study (CCSS), a retrospective cohort study of children diagnosed with cancer from 1970–1999 at 31 participating…

The randomised, double-blind, phase 3 CheckMate 067 trial showed that nivolumab alone or nivolumab plus ipilimumab significantly improved progression…

Findings from the PERSIST-1 study of patients with myelofibrosis suggest that pacritinib is significantly more effective than best available therapy…

Interim analysis of a phase III study finds that adding the new anti-CD20 monoclonal antibody obinutuzumab to standard bendamustine chemotherapy…

A phase II trial suggests that anti-CD38 antibody daratumumab is effective as a standalone therapy for heavily treated multiple myeloma. In a group of…

An interim analysis of a large phase III study suggests that the combination of ibrutinib and bendamustine/rituximab (BR) improves outcomes for patients…

A phase II study identified the first genomic marker – mismatch repair (MMR) deficiency – to predict response to the anti-PD-1 antibody pembrolizumab…

Findings from a randomised phase III study indicate that PD-1 immunotherapy is an effective treatment option for patients with non-squamous, non-small…

Peter Paul Yu, MD, FACP, FASCO introduces ASCO 2015 and the conference themes – how to utilise data, to transform it into learning to impact patient care.

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof. Dr. med. Peter Fasching (Friedrich-Alexander-Universität Erlangen-Nürnberg…

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof. Dr. med. Michael Untch (HELIOS Klinikum Berlin-Buch, Berlin, Germany) and Prof…